John B Buse Selected Research

Insulin Glargine (Lantus)

11/2021	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE.
1/2021	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
1/2021	Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.
1/2020	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11).
10/2019	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
1/2019	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
1/2019	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
11/2018	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
6/2018	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.
1/2018	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John B Buse Research Topics

Disease

159	Type 2 Diabetes Mellitus (MODY) 11/2022 - 07/2002
40	Hypoglycemia (Reactive Hypoglycemia) 11/2021 - 07/2009
34	Cardiovascular Diseases (Cardiovascular Disease) 11/2022 - 06/2008
29	Stroke (Strokes) 11/2021 - 11/2002
28	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 07/2010
27	Myocardial Infarction 11/2021 - 11/2002
21	Heart Failure 11/2022 - 08/2003
19	Hyperglycemia 12/2021 - 01/2002
19	Body Weight (Weight, Body) 04/2021 - 01/2007
14	Weight Loss (Weight Reduction) 12/2020 - 11/2004
11	Chronic Renal Insufficiency 11/2022 - 11/2018
10	Nausea 12/2019 - 07/2009
9	Neoplasms (Cancer) 10/2020 - 07/2011
8	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 09/2015
8	Dyslipidemias (Dyslipidemia) 01/2020 - 07/2002
8	Weight Gain 01/2019 - 06/2009
7	Pancreatitis 01/2018 - 07/2011
6	COVID-19 11/2022 - 01/2021
6	Diabetes Mellitus 11/2020 - 02/2003
6	Insulin Resistance 01/2018 - 06/2003
5	Ketosis 01/2022 - 09/2015
5	Obesity 01/2020 - 03/2005
5	Acute Coronary Syndrome 01/2020 - 09/2013
5	Unstable Angina 12/2019 - 04/2010
4	Peripheral Arterial Disease 10/2021 - 01/2018
4	Infections 10/2021 - 09/2018
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 04/2016
4	Vomiting 09/2015 - 01/2011
4	Inflammation (Inflammations) 09/2013 - 06/2011
3	Hypertension (High Blood Pressure) 01/2021 - 02/2013
3	Diabetes Complications 10/2019 - 06/2018
3	Diarrhea 09/2018 - 01/2011
3	Glucose Intolerance 04/2010 - 01/2002
2	Kidney Diseases (Kidney Disease) 11/2022 - 01/2018
2	Albuminuria 01/2022 - 01/2021
2	Vascular Diseases (Vascular Disease) 11/2020 - 01/2016
2	Overweight 01/2020 - 03/2016
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 01/2017
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2019 - 01/2019

Drug/Important Bio-Agent (IBA)

71	Insulin (Novolin)FDA Link 01/2022 - 06/2003
58	Glucose (Dextrose)FDA LinkGeneric 11/2022 - 01/2002
38	Liraglutide FDA Link 01/2022 - 07/2009
24	Insulin Glargine (Lantus)FDA Link 11/2021 - 06/2009
22	Exenatide (Byetta)FDA Link 01/2020 - 07/2003
19	Metformin (Glucophage)FDA LinkGeneric 04/2021 - 01/2004
18	LipidsIBA 01/2020 - 01/2004
16	Blood Glucose (Blood Sugar)IBA 11/2022 - 07/2015
16	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2013
15	insulin degludecIBA 11/2021 - 11/2014
15	Glucagon-Like Peptide-1 ReceptorIBA 04/2021 - 07/2009
15	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2020 - 10/2008
15	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 07/2003
14	omega-Chloroacetophenone (Mace)IBA 11/2021 - 07/2011
13	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2022 - 07/2015
12	semaglutideIBA 01/2022 - 01/2019
12	Sitagliptin Phosphate (Januvia)FDA Link 04/2021 - 07/2015
12	Pharmaceutical PreparationsIBA 01/2021 - 08/2005
12	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020 - 01/2007
11	Sodium-Glucose Transport ProteinsIBA 01/2021 - 07/2015
8	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 07/2015
8	IncretinsIBA 01/2018 - 11/2004
7	SodiumIBA 11/2022 - 11/2018
7	Hemoglobins (Hemoglobin)IBA 11/2021 - 05/2009
7	Pioglitazone (Actos)FDA Link 01/2019 - 01/2004
6	CreatinineIBA 01/2021 - 01/2017
6	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2021 - 07/2015
6	Fenofibrate (CiL)FDA LinkGeneric 01/2020 - 04/2010
6	Triglycerides (Triacylglycerol)IBA 01/2017 - 07/2002
5	ThiazolidinedionesIBA 11/2020 - 08/2003
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2020 - 08/2005
5	Fibric Acids (Fibrates)IBA 01/2020 - 06/2007
5	HDL CholesterolIBA 01/2017 - 07/2002
5	2,4-thiazolidinedione (thiazolidinedione)IBA 07/2011 - 01/2004
4	KetonesIBA 01/2021 - 09/2015
4	LDL CholesterolIBA 01/2020 - 11/2007
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 06/2007
4	aleglitazarIBA 01/2018 - 09/2013
4	Insulin Lispro (Humalog)FDA Link 07/2011 - 05/2009
4	Rosiglitazone (Avandia)FDA Link 07/2009 - 01/2004
3	TTP399IBA 01/2022 - 01/2019
3	GlucokinaseIBA 01/2022 - 01/2019
3	Peptides (Polypeptides)IBA 04/2021 - 09/2009
3	SymportersIBA 11/2020 - 11/2018
3	AlbuminsIBA 01/2020 - 01/2020
3	Nonesterified Fatty Acids (NEFA)IBA 01/2018 - 07/2002
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016 - 07/2002
3	IDegLiraIBA 10/2015 - 11/2014
3	Lipoproteins (Lipoprotein)IBA 08/2013 - 10/2007
3	Biomarkers (Surrogate Marker)IBA 07/2012 - 01/2007
3	1,5-anhydroglucitolIBA 06/2012 - 06/2006
2	Glucagon (Glukagon)FDA Link 11/2020 - 01/2017
2	CanagliflozinIBA 01/2020 - 11/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2009
2	EnzymesIBA 01/2019 - 01/2017

Therapy/Procedure

58	Therapeutics 11/2022 - 01/2004
34	Glycemic Control 01/2021 - 01/2004
9	Injections 01/2021 - 07/2010
6	Surgical Amputation (Amputations) 10/2021 - 11/2002
2	Precision Medicine 01/2022 - 06/2013
2	Aftercare (After-Treatment) 01/2021 - 01/2018